NASDAQ:ONTX - Onconova Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Onconova Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.29 -0.02 (-6.41 %) (As of 12/5/2019 04:00 PM ET) Add Compare Today's Range$0.26Now: $0.29▼$0.3150-Day Range$0.13MA: $0.47▼$1.0152-Week Range$0.10Now: $0.29▼$4.83Volume18.85 million shsAverage Volume1.62 million shsMarket Capitalization$1.75 millionP/E RatioN/ADividend YieldN/ABeta2.22 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONTX Previous Symbol CUSIPN/A CIK1130598 Webhttp://www.onconova.com/ Phone267-759-3680Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.23 million Price / Sales1.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book0.31Profitability EPS (Most Recent Fiscal Year)($4.99) Net Income$-20,570,000.00 Net Margins-967.77% Return on Equity-872.01% Return on Assets-195.28%Miscellaneous Employees25 Outstanding Shares5,998,000Market Cap$1.75 million Next Earnings Date3/24/2020 (Estimated) OptionableNot Optionable Receive ONTX News and Ratings via Email Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ONTX Rates by TradingView Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions What is Onconova Therapeutics' stock symbol? Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX." When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work? Onconova Therapeutics's stock reverse split before market open on Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics Inc (NASDAQ:ONTX) announced its quarterly earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.15. The biopharmaceutical company earned $0.49 million during the quarter, compared to analyst estimates of $0.52 million. Onconova Therapeutics had a negative net margin of 967.77% and a negative return on equity of 872.01%. View Onconova Therapeutics' Earnings History. When is Onconova Therapeutics' next earnings date? Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Onconova Therapeutics. What price target have analysts set for ONTX? 3 Wall Street analysts have issued twelve-month target prices for Onconova Therapeutics' stock. Their forecasts range from $8.00 to $25.00. On average, they expect Onconova Therapeutics' share price to reach $15.00 in the next year. This suggests a possible upside of 5,035.2% from the stock's current price. View Analyst Price Targets for Onconova Therapeutics. What is the consensus analysts' recommendation for Onconova Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Onconova Therapeutics. What are Wall Street analysts saying about Onconova Therapeutics stock? Here are some recent quotes from research analysts about Onconova Therapeutics stock: 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (10/30/2019) 2. Maxim Group analysts commented, "Onconova announced that it has entered into a license agreement with HanX Biopharmaceuticals, Inc. (HanX, private) in China to develop and commercialize the company’s lead asset, rigosertib, which is currently in an ongoing pivotal P3 study (INSPIRE) for the treatment of higher-risk MDS (HR-MDS). This expands the collaboration with HanX, which already includes Onconova’s ON 1233000 (CDK 4/6 + ARK5 inhibitor)." (5/14/2019) 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $25 price target. Our clinical NPV model, driven by rigostertib in MDS, allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Onconova Therapeutics, Inc." (2/8/2019) Has Onconova Therapeutics been receiving favorable news coverage? News headlines about ONTX stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Onconova Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Onconova Therapeutics. Who are some of Onconova Therapeutics' key competitors? Some companies that are related to Onconova Therapeutics include Nuvo Pharmaceuticals (NRIFF), IntelliPharmaCeutics Intl (IPCIF), International Stem Cell (ISCO), Wellness Center USA (WCUI), Immune Therapeutics (IMUN), Innovus Pharmaceuticals (INNV), Auris Medical (EARS), Innovus Pharmaceuticals (INNVD), Endonovo Therapeutics (ENDV), Parnell Pharmaceuticals (PARNF), Global Future City (FTCY), American Bio Medica (ABMC), Diffusion Pharmaceuticals (DFFN), Ritter Pharmaceuticals (RTTR) and Tonix Pharmaceuticals (TNXP). What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Crispr Therapeutics (CRSP), Cytori Therapeutics (CYTX), Sorrento Therapeutics (SRNE), IDT (IDT), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Alibaba Group (BABA), Celldex Therapeutics (Cldx) and Corbus Pharmaceuticals (CRBP). Who are Onconova Therapeutics' key executives? Onconova Therapeutics' management team includes the folowing people: Dr. Steven M. Fruchtman, CEO, Pres & Director (Age 68)Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 75)Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 56)Dr. Ramesh Kumar, Advisor (Age 63)Mr. Mark Patrick Guerin, Chief Financial Officer (Age 50) Who are Onconova Therapeutics' major shareholders? Onconova Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sabby Management LLC (13.38%) and Tyndall Capital Partners L P (10.27%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, Henry S Bienen, James J Marino, Mark Patrick Guerin, Michael B Hoffman, Steven M Fruchtman and Tyndall Capital Partners L P. View Institutional Ownership Trends for Onconova Therapeutics. Which major investors are selling Onconova Therapeutics stock? ONTX stock was sold by a variety of institutional investors in the last quarter, including Tyndall Capital Partners L P. Company insiders that have sold Onconova Therapeutics company stock in the last year include 683 Capital Management, Llc and Tyndall Capital Partners L P. View Insider Buying and Selling for Onconova Therapeutics. Which major investors are buying Onconova Therapeutics stock? ONTX stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, Henry S Bienen, James J Marino, Mark Patrick Guerin and Steven M Fruchtman. View Insider Buying and Selling for Onconova Therapeutics. How do I buy shares of Onconova Therapeutics? Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $0.29. How big of a company is Onconova Therapeutics? Onconova Therapeutics has a market capitalization of $1.75 million and generates $1.23 million in revenue each year. The biopharmaceutical company earns $-20,570,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.View Additional Information About Onconova Therapeutics. What is Onconova Therapeutics' official website? The official website for Onconova Therapeutics is http://www.onconova.com/. How can I contact Onconova Therapeutics? Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected] MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 276 (Vote Outperform)Underperform Votes: 243 (Vote Underperform)Total Votes: 519MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/5/2019 by MarketBeat.com StaffFeatured Article: What are municipal bonds?
